Peter Alping

Peter Alping
Karolinska Institutet | KI · Department of Clinical Neuroscience

Master of Science in Medicine

About

6
Publications
2,158
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
730
Citations
Introduction
I'm a PhD student at the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. My research is mainly focused around pharmacoepidemiological studies of disease modifying drugs for multiple sclerosis, with a special interest in rituximab.
Additional affiliations
June 2016 - present
Karolinska Institutet
Position
  • PhD Student
Education
August 2011 - January 2017
Karolinska Institutet
Field of study
  • Medicine

Publications

Publications (6)
Article
Full-text available
Objective: To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT), compared to non-induction disease-modifying therapies. Methods: We performed a population-based cohort study linking the Swedish Multiple Sclerosis Register to national healthcare registers. Alemtuzumab, AH...
Article
Full-text available
Objective: Novel, highly effective disease-modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking. Methods: In this nationwide register-based cohort study, we linked data from the Swedish MS register to the Swedish Cancer...
Article
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk increase is not well established in real-world populations. Even less is known about infection ris...
Article
Full-text available
The Swedish Multiple Sclerosis Register is a national register monitoring treatment and clinical course for all Swedish multiple sclerosis (MS) patients, with high coverage and close integration with the clinic. Despite its great value for epidemiologic research, it has not previously been validated. In this brief report, we summarize a large valid...
Article
Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). Methods: In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (...
Article
Objective: Many JC-virus antibody positive relapsing-remitting multiple sclerosis (RRMS) patients stable on natalizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy. Methods: We compared outcomes for all RRMS patients switching from natalizumab due to JC-virus antibody positivity at three Swedish MS centres with...

Network

Cited By

Projects

Project (1)
Project
Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis